7:48 am Johnson & Johnson’s Janssen submits snDA to FDA for OLYSIO (simeprevir) for once-daily use in combinaiton with sofosbuvir for 12 weeks for the treatment of adult patients with genotype 1 chronic hepatitis C
View todays social media effects on JNJ
View the latest stocks trending across Twitter. Click to view dashboard
See who Johnson is hiring next, click here to view
